ea0063p1027 | Interdisciplinary Endocrinology 2 | ECE2019
Poli Roberta
, Dumont Clement
, Pietrogiovanna Lisa
, Servois Vincent
, Beaucaire-Danel Sophie
, Daniel Catherine
, Girard Nicolas
, Romano Emanuela
, Hescot Segolene
Background: Immune checkpoint inhibitors (ICIs) are approved for the treatment of non-small cell lung cancer (NSCLC) and are associated with specific immune-related adverse events (iRAEs) including endocrine toxicities. However, data concerning the type, occurrence, and dynamics of iRAEs and their predictive value on treatment outcome are lacking. In this study, we evaluated the relation of iRAEs to anti-PD/L1 (programmed cell death protein/ligand-1) ICIs focusing particularly...